Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Isolated Restricted Diffusion at Admission Predicts Survival in Patients of Glioblastoma Multiforme (IRD GBM)- A Prospective Pilot Study

NCT05402241 is registered in ClinicalTrials.gov with University of Manitoba as lead sponsor.

NCT NCT05402241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05402241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Isolated Restricted Diffusion at Admission Predicts Survival in Patients of Glioblastoma Multiforme (IRD GBM)- A Prospective Pilot Study
Lead sponsor
University of Manitoba
Phase
Observational
Overall status
Completed
Start date
October 21, 2021
Completion date
November 15, 2023
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme